Aquaculture: NaturalShrimp Terminates Merger Agreement; Announces Re-IPO Opportunity for Uplist

Dallas-based NaturalShrimp recently signed an agreement with Japan's Niterra to trial its patented technology in Japanese aquaculture farms for shrimp production.

NaturalShrimp Inc., a Dallas-based biotechnology aquaculture company, has terminated its previously announced merger agreement with Yotta Acquisition Corp., a deal that was anticipated as the first use of a special purpose acquisition company in the nation’s seafood sector.

It said, however, that it’s in negotiations with another entity that would involve a re-IPO and new capital raise. Last year, we gave you a look at NaturalShrimp and its plans.

The company, which developed and patented the first shrimp-focused commercially operational Recirculating Aquaculture System, said it terminated the deal because Yotta is unable to comply with the provision of its amended and restated certificate of incorporation.

The company said that prohibits Yotta from consummating an acquisition unless it has net tangible assets of at least $5,000,001 upon consummation of such a transaction.

“After working on this for almost 12 months, we are naturally disappointed in this news,” William Delgado, CFO and treasurer of NaturalShrimp, said in a statement. “We are currently in negotiations with another entity which will involve a Re-IPO and a new capital raise of between $10-$12M.”

“This opportunity has the full support of management, its advisors, and its investment banking team. The timing of this Re-IPO, if executed, will result in an uplist on similar timing as the previous business combination agreement. That timetable for the uplist remains at the end of September-beginning of October,” Delgado said. “Our team remains highly focused on commercialization and production ramp up of farm-to-table sushi grade shrimp and fresh seafood including a planned U.S. facility expansion, and we look forward to additional announcements in the weeks to come.”

First-of-its-kind farm-fresh shrimp and SPAC details

A publicly traded company, NaturalShrimp has production facilities near San Antonio and Webster City, Iowa.

It developed the first commercially viable system for growing shrimp in enclosed salt-water systems using patented technology to produce fresh, naturally grown shrimp, without the use of antibiotics or toxic chemicals.

NaturalShrimp announces licensing agreement with Japan-based Niterra

NaturalShrimp signed a technology licensing agreement with Niterra Co., Ltd., a leading Japanese manufacturer of spark plugs that also explores opportunities in various business sectors, including food and the environment.

The deal marks the first Asian license for NaturalShrimp’s technology, expanding its reach into one of the world’s largest seafood markets, according to a news release in June.

An agreement allows Niterra to trial NaturalShrimp’s patented shrimp-growing tech, including its Electrocoagulation and Hydroga technologies, in small-scale aquaculture farms in Japan. A six-month trial aims to evaluate the viability of these technologies in enhancing shrimp cultivation within local aquaculture farms. Niterra plans to conduct further tests on additional aquatic species upon successful completion.

If successful, Niterra might conduct further studies to evaluate the efficacy of NaturalShrimp’s technologies on other aquatic species.

Get on the list.
Dallas Innovates, every day.

Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.

One quick signup, and you’re done.  

R E A D   N E X T

  • Bio 9 Ventures, a Plano-based boutique healthcare ecosystem consulting firm, has merged its international healthcare IT division with three companies to form a new business called Kanectify. The new entity will add end-to-end integrated benefits to platform engineering, AI healthcare, and a portfolio of digital health R&D solutions.

  • Financial Strategies Acquisition Corp. Acquires Preclinical Pharma Company

    Dallas-based Financial Strategies Acquisition Corp. has acquired Texas-based preclinical pharmaceutical company Austin Biosciences Corp. Financial Strategies is a special purpose acquisition company led by CEO Alexander V. Schinzing. It said that upon the deal's closing, Austin Biosciences will become a wholly owned subsidiary of the company. Earlier this month, Financial Strategies announced that its board approved an extension of the period of time available to consummate the deal by one month from Feb. 14 to March 14. The company said the purpose of the extension is to provide additional time to complete its initial business combination. Schinzing will serve as chairman and…

  • Blackboxstocks Announces $8.5M Investment Stake in UK's Evtec Group as Step Toward Merger

    The planned merger is between Dallas-based Blackbox and Evtec Group Limited, Evtec Aluminium Limited, and Evtec Automotive Limited. The merger was previously announced on April 17. 

  • Illustration of the Orthofix FIREBIRD SI Fusion System with NANOVATE technology [PHOTO: Business Wire]

    Lewisville-based Orthofix will merge with and into California-based SeaSpine, completing a previously announced merger of equals. “The completion of this merger catalyzes our ambition to be an industry leader in spine and orthopedics,” said Keith Valentine, president and CEO of Orthofix. "Together we are stronger and better positioned to deliver innovative, quality-driven solutions for surgeons in their work to improve patients’ lives.”

  • BGSF CEO Beth Garvey says the addition of the Nashville-based workforce solutions firm allows the company to offer software development and IT consulting services and solutions using resources located outside of the U.S.